MIC-1 Serum Biomarker for Prostate Cancer Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting prostate cancer progression and overall survival are inadequate, particularly in distinguishing between benign and aggressive prostate cancer, leading to unnecessary aggressive treatments and challenges in accurately predicting disease outcomes.
Innovation Solution
The use of elevated macrophage inhibitory cytokine-1 (MIC-1) serum concentrations as a biomarker to predict prostate cancer progression and overall survival, allowing for more informed treatment decisions and reducing unnecessary treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If Gleason sum analysis is used to determine prostate cancer severity, then prognosis accuracy is improved, but the method becomes invasive and expensive requiring biopsy and histological analysis
Solution Approach 1:
The patent extracts the prognostic information from invasive tissue biopsy and transfers it to a non-invasive serum-based assay. By measuring MIC-1 levels in serum instead of performing histological analysis of prostate tissue, the method achieves similar prognostic accuracy without requiring biopsy, thereby eliminating the invasiveness and complexity of the original method.
Solution Approach 2:
The patent introduces MIC-1 serum levels as an intermediary biomarker that correlates with prostate cancer aggressiveness. This intermediary allows clinicians to assess prognosis without directly examining prostate tissue, serving as a mediator between the patient's condition and the diagnostic process, thus avoiding invasive procedures while maintaining diagnostic value.
2Ease of operation
If PSA testing is used to diagnose prostate cancer, then detection is simplified, but accuracy is reduced leading to concerns about false positives
Solution Approach 1:
The patent combines PSA testing with MIC-1 serum level measurement to create a more accurate diagnostic approach. By merging these two biomarkers, the method maintains the simplicity of blood-based testing while improving diagnostic accuracy, as MIC-1 provides additional prognostic information that complements PSA and reduces false positives.
Solution Approach 2:
The patent creates a composite diagnostic approach using multiple biomarkers (PSA and MIC-1) in serum. This composite method leverages the strengths of each individual marker while compensating for their weaknesses, providing both the simplicity of blood testing and the accuracy of multi-marker analysis.
3Reliability
If active treatment is applied to all prostate cancer patients, then prognosis is improved for aggressive cases, but morbidity increases due to side effects in benign cases
Solution Approach 1:
The patent applies local quality by tailoring treatment to individual patient risk profiles based on MIC-1 levels. Instead of uniform treatment for all prostate cancer patients, the method identifies specific subgroups (high MIC-1 indicating aggressive disease) who benefit from active treatment, while sparing low-risk patients (low MIC-1 indicating benign course) from unnecessary treatment side effects.
Solution Approach 2:
The patent uses MIC-1 serum levels as a parameter to stratify patients into different treatment categories. By changing the decision parameter from binary (cancer present/absent) to continuous (MIC-1 level stratification), the method enables nuanced treatment decisions that match treatment intensity to disease aggressiveness, improving outcomes while reducing harmful effects.
Data Source
Figure 1
Figure 2
Figure 3A~3C
AI summary
The invention relates to the field of medical prognostics. In particular, the invention relates to methods for predicting prostate cancer progression and overall survival prognosis in a subject involving the detection of elevated amounts of macrophage inhibitory cytokine- 1 (MIC-I) in a test body sample such as serum.